Advertisement

Eric Jonasch, MD

Articles

Dr. Jonasch on the Promise of Belzutifan in Metastatic RCC

November 22nd 2022

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Future Directions in the Management of Renal Cell Carcinoma

November 10th 2022

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

November 10th 2022

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Dr. Jonasch on the Exploration of Cabozantinib in the Neoadjuvant Setting in RCC

November 4th 2022

Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.

Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape

November 3rd 2022

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Advanced Clear Cell RCC: Optimal Selection and Sequencing of Second-Line Therapy

November 3rd 2022

Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.

Treatment Options for Advanced Clear Cell RCC in the Second-Line and Beyond

October 27th 2022

Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.

Is There a Role for Adjuvant Therapy in Advanced Clear Cell RCC?

October 27th 2022

Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.

First-Line Therapy in Advanced Clear Cell RCC: Novel Triplet Regimens

October 20th 2022

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

October 20th 2022

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Advanced Clear Cell RCC: Quality of Life Data in First-Line Clinical Trials

October 13th 2022

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Treating Patients with Clear Cell RCC with Brain Metastases or Sarcomatoid Disease

October 13th 2022

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Advanced Clear Cell RCC: Role of Site of Metastases in Selecting First-Line Therapy

October 6th 2022

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Selecting the Appropriate First-Line Therapy in Advanced Clear Cell RCC

October 6th 2022

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

What is the Role of Nephrectomy in Advanced Clear Cell RCC?

September 29th 2022

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Overview on Clear Cell Renal Cell Carcinoma: Prevalence and Prognosis

September 29th 2022

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.

Dr. Jonasch on the Target Population for Treatement with Belzutifan in RCC

August 24th 2022

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Dr. Jonasch on the Future of Belzutifan in Clear Cell RCC

August 11th 2022

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Dr. Jonasch on the Investigation of Belzutifan in ccRCC

July 8th 2022

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

Advanced Renal Cell Carcinoma: Clinical Practice Pearls

April 4th 2022

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Advertisement
Advertisement